Founded in 2008, argenx SE is a global, fully integrated immunology company with its official seat and registered office in Amsterdam, the Netherlands, focused on developing differentiated antibody-based therapies for severe autoimmune diseases. Built around a proprietary antibody engineering platform and its Immunology Innovation Program, the company has developed into one of Europe’s leading biotechnology businesses, combining scientific innovation with growing commercial scale across international markets. argenx commercializes the VYVGART franchise, the first approved FcRn blocker, now approved in more than 30 countries, and continues to advance a deep pipeline that includes empasiprubart and multiple additional clinical and discovery-stage programs. As of December 31, 2024, the company had 1,599 employees and 774 contingent workers. In 2024, global product net sales from VYVGART IV and VYVGART SC reached $2.2 billion, and argenx recorded an annual profit of $833 million.
Updated 2026-03-19